Regeneron Pharmaceuticals Inc
REGN Real Time Price USDRecent trades of REGN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in REGN holdings by institutional investors
Quarterly net insider trading by REGN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$570,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$610,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$400,000 Apr 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
-
$400,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$400,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$430,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$430,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jul 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$340,000 Jul 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Apr 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jan 20, 2022 Issue: None
-
$360,000 Oct 20, 2021 Issue: None
-
$310,000 Jul 20, 2021 Issue: None
-
$330,000 Apr 20, 2021 Issue: None
-
$330,000 Jan 21, 2021 Issue: None
-
$480,000 Oct 20, 2020 Issue: None
-
$320,000 Jul 20, 2020 Issue: None
-
$370,000 Apr 20, 2020 Issue: None
-
$340,000 Jan 21, 2020 Issue: None
-
$180,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$250,000 Jul 22, 2019 Issue: Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$300,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$180,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$190,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$200,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$260,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$120,000 Oct 20, 2017 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$120,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Budget/Appropriations
-
$240,000 Apr 20, 2017 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$130,000 Jan 20, 2017 Issue: Health Issues Medicare/Medicaid
-
$130,000 Oct 20, 2016 Issue: Health Issues
-
$120,000 Jul 20, 2016 Issue: Health Issues
-
$50,000 Apr 19, 2016 Issue: Health Issues
-
$50,000 Jan 16, 2016 Issue: Health Issues
-
$50,000 Oct 20, 2015 Issue: Health Issues
-
$50,000 Jul 20, 2015 Issue: Health Issues
-
$60,000 Apr 20, 2015 Issue: Health Issues
-
$52,000 Jan 19, 2015 Issue: Health Issues
-
$50,000 Oct 20, 2014 Issue: Health Issues
-
$50,000 Jul 21, 2014 Issue: Health Issues
-
$50,000 Jan 22, 2014 Issue: Health Issues
-
$50,000 Oct 21, 2013 Issue: Health Issues
-
$40,000 Jul 22, 2013 Issue: Health Issues
-
$30,000 Apr 24, 2013 Issue: Health Issues
-
$30,000 Feb 02, 2013 Issue: Health Issues
-
$30,000 Oct 31, 2012 Issue: Health Issues
REGN Estimated quarterly lobbying spending
REGN Revenue by Segment or Geography
New REGN patent grants
-
Patent Title: Non-human animals having an engineered immunoglobulin lambda light chain locus Oct. 07, 2025
-
Patent Title: Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation Sep. 23, 2025
-
Patent Title: Polynucleotides encoding anti-glucagon-like peptide 1 receptor (glp1r) antagonist antibodies Sep. 23, 2025
-
Patent Title: Cll-1 targeted immunotherapies Sep. 23, 2025
-
Patent Title: Diels-alder conjugation methods Sep. 23, 2025
-
Patent Title: Non-human animals expressing humanized cd3 complex Sep. 23, 2025
-
Patent Title: Egfr x cd28 multispecific antibodies Sep. 16, 2025
-
Patent Title: Genetically modified major histocompatibility complex mice Sep. 16, 2025
-
Patent Title: Lc-ms methods for antibody isotyping and quantification Sep. 09, 2025
-
Patent Title: Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems Sep. 09, 2025
-
Patent Title: Bracketing device for manufacturing parts cleaner and methods therefor Sep. 02, 2025
-
Patent Title: Delivery of a gene-editing system with a single retroviral particle and methods of generation and use Sep. 02, 2025
-
Patent Title: Genetically modified mice and engraftment Sep. 02, 2025
-
Patent Title: Quantitation and identification of dimers in co-formulations Aug. 26, 2025
-
Patent Title: Compositions and methods for detecting a biological contaminant Aug. 26, 2025
-
Patent Title: Use of raman spectroscopy in downstream purification Aug. 26, 2025
-
Patent Title: Adoptive cellular therapy Aug. 26, 2025
-
Patent Title: Tuning of release kinetics in hydrogels Aug. 26, 2025
-
Patent Title: Mouse comprising a humanized trkb locus Aug. 26, 2025
-
Patent Title: Models of tauopathy Aug. 19, 2025
-
Patent Title: Antigen binding molecule formats Aug. 19, 2025
-
Patent Title: Pd-1 homing endonuclease variants, compositions, and methods of use Aug. 19, 2025
-
Patent Title: Mouse having a humanized cluster of differentiation 47 gene Aug. 19, 2025
-
Patent Title: Mice expressing a limited immunoglobulin light chain repertoire Aug. 19, 2025
-
Patent Title: Treatment of sepsis with pcsk9 and ldlr modulators Aug. 05, 2025
-
Patent Title: Biologically active molecules, conjugates thereof, and therapeutic uses Aug. 05, 2025
-
Patent Title: Retainer adapter assembly Jan. 14, 2025
-
Patent Title: Packaging Oct. 22, 2024
-
Patent Title: Packaging Sep. 17, 2024
-
Patent Title: Support for test device Aug. 20, 2024
-
Patent Title: Packaging Jul. 16, 2024
-
Patent Title: Retainer adapter assembly May. 21, 2024
-
Patent Title: Retainer adapter assembly Apr. 23, 2024
-
Patent Title: Wearable autoinjector Dec. 12, 2023
-
Patent Title: Packaging Aug. 23, 2022
-
Patent Title: Packaging Aug. 23, 2022
-
Patent Title: Auto-injector cap Jul. 26, 2022
-
Patent Title: Genetically modified mouse with an inducible acvr1 gene with a mutant r206h exon 5 that has ectopic bone formation Jul. 05, 2022
-
Patent Title: Packaging Oct. 26, 2021
-
Patent Title: Auto-injector cap Sep. 28, 2021
-
Patent Title: Production cell line enhancers Jul. 20, 2021
-
Patent Title: Packaging Dec. 29, 2020
-
Patent Title: Auto-injector Dec. 01, 2020
-
Patent Title: Syringe cap Sep. 03, 2019
-
Patent Title: Nucleic acid construct for making a genetically modified rodent with an inducible acvr1 mutation that causes ectopic bone formation Jun. 19, 2018
-
Patent Title: Human antibodies to pd-1 Jun. 05, 2018
-
Patent Title: Genetically modified non-human animals and methods of use thereof Jun. 05, 2018
-
Patent Title: Readily isolated bispecific antibodies with native immunoglobulin format May. 29, 2018
-
Patent Title: Humanized il-7 rodents May. 22, 2018
-
Patent Title: Methods for making fully human bispecific antibodies using a common light chain May. 15, 2018
Federal grants, loans, and purchases
- $494,095 2021-11-24 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-09-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $148,229 2021-09-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-04-07 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $2,625,000,000 2021-01-12 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
Estimated quarterly amount awarded to REGN from public contracts
Recent insights relating to REGN
Recent picks made for REGN stock on CNBC
ETFs with the largest estimated holdings in REGN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $REGN stock a Buy, Sell, or Hold?
- What is the price target for $REGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $REGN stock?
- Who owns the most shares of $REGN stock?
- What funds own $REGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view REGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
- Address Tarrytown, NY
- Market Cap 79.4 billion
- Employees 15,207
- Industrial Classification Pharmaceutical Preparations